Incomplete invention of drugs.
Scientists seldom know the differences between "rejected invention", "non-invention", "incomplete invention", "invention yet to be completed" and "defective invention". The Japanese Supreme Court appointed me as a specialist member (Article 92-2, Code of Civil Procedure) of intellectual property division for medical and biological patents. Herein, I present scientists to the differences and which of them are patentable. In order to prevent oneself from being taken for granted for the scientists' noblesse oblige by clever business administrations, the scientists must know the borderline between patentable or non-patentable.
Hisa
Tomoyuki
T
University of Tokyo, Rm670, Bldg4, RCAST, 4-6-1 Komaba, Meguro, Tokyo, 153-8904, Japan. pa2022@art.osaka-med.ac.jp
D001688:Biological Products; D018973:Intellectual Property; D007564:Japan; D007603:Jurisprudence; D007880:Legislation, Drug; D010067:Ownership / Q000331:legislation & jurisprudence; D010330:Patents as Topic / Q000331:legislation & jurisprudence*
D001688:Biological Products